drugset / Trial / NCT00440427

Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)

NCT00440427

Phase 1 Completed 12 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

To assess the initial pharmacokinetic profile of single doses of 25mg and 50 mg of DVS SR to healthy subjects.

Timeline

Start
2007-02
Primary completion
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Desvenlafaxine Other / unclassified 25 mg
Subject Desvenlafaxine Other / unclassified 50 mg